Qiagen plans to submit a second gastrointestinal panel covering five of the most common bacterial pathogens responsible for gastrointestinal infections – Campylobacter, Salmonella, STEC ...

Qiagen has received clearance from U.S. regulators to market its gastrointestinal-illness test. The Netherlands life-sciences and diagnostics company said Thursday that the Food and Drug ...

The anticipated deceleration in Qiagen’s TB test growth, notably from 24% in FY23 to an estimated 8% in the following year, reflects a normalization of testing demand. Additionally, emerging ...

Qiagen said the intellectual property in question covers technologies used in its QuantiFeron latent tuberculosis assays.